Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C

Abstract

Eltrombopag therapy increases platelet counts in patients with thrombocytopenia due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy. (ClinicalTrials.gov number, NCT00110799.)